Infliximab Injection Uses, Dosage, Side Effects and Interactions
Inflectra
Inflectra (infliximab-dyyb) is Celltrion’s biosimilar to Remicade, approved by the FDA in April 2016. The FDA has not rated it interchangeable with Remicade.
Renflexis
Renflexis (infliximab-abda) is Samsung Bioepis’s biosimilar to Remicade, approved by the FDA in April 2017. The FDA has not rated it interchangeable with Remicade. It comes as an injection.
Remicade
Remicade is the original infliximab, made by Janssen Biotech. Its biosimilars are Inflectra, Renflexis, Ixifi and Avsola. It comes as an injection.
Avsola
Avsola (infliximab-axxq) is Amgen’s biosimilar to Remicade, approved by the FDA in December 2019. The FDA has not rated it interchangeable with Remicade.
Zymfentra
Zymfentra is an original infliximab product of its own: the FDA lists it as an original, not a biosimilar.
Remicade is the original infliximab. The FDA has approved 4 biosimilars of it, such as Inflectra and Renflexis, and they share this page. What is a biosimilar? ↓
Infliximab Injection is a TNF blocker given by IV infusion to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
Quick links
Ask Anything About Infliximab InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Infliximab Injection in Short
- Drug class Tumor Necrosis Factor Blocker How the FDA classifies it
What it treatsInfliximab is a tumor necrosis factor (TNF) blocker. It is used for several long-term inflammatory conditions, mostly when other treatments have not worked well enough. Renflexis is described in the label evidence for all of the uses below. Follow your prescriber's guidance for which product is right for you.
- How you get it Prescription only
- Comes asInjection (into a vein)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- What pharmacies pay
- Remicade (brand)$1,135.97 each
The Pharmacist’s Take
Infliximab Injection is a strong biologic medicine that blocks TNF-alpha, an inflammation signal, from reaching its receptors. It is used when standard treatments fall short for Crohn's disease, ulcerative colitis, rheumatoid arthritis (with methotrexate), ankylosing spondylitis, psoriatic arthritis and severe plaque psoriasis; on the U.S. market since about 1998, it is one of the most familiar biologics, and FDA-licensed biosimilars exist. Most people handle the infusions well, noticing mainly colds, sinus infections or headache, and sometimes flushing, rash or chills during an infusion. Its boxed warning covers serious infections, including tuberculosis and fungal infections, plus lymphoma and other cancers, so report fever, cough, weight loss or unusual tiredness right away.
Key Takeaways From the HelloPharmacist Team
- Expect an IV infusion in a clinic at weeks 0, 2 and 6, then every 8 weeks (every 6 weeks for ankylosing spondylitis).
- Get tested for tuberculosis and hepatitis B before the first infusion, and mention any past TB or living where TB is common.
- Tell the nurse at once if you get short of breath, hives, facial swelling or chest pain during or soon after an infusion.
- Ask before any vaccine, since live vaccines should not be given with infliximab, and call ahead if you are sick before an infusion.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Infliximab Injection.
Infliximab products raise the risk of serious infections that can lead to hospitalization or death. These include tuberculosis, bacterial blood infections (sepsis) and invasive fungal infections. Most serious cases happened in people also taking immunosuppressants such as methotrexate or corticosteroids.
You should be tested for TB before and during treatment. Treatment should stop if a serious infection develops.
Lymphoma and other cancers, some fatal, have been reported in children and teens taking TNF blockers. A rare, aggressive cancer called hepatosplenic T-cell lymphoma has occurred mostly in teen and young adult males with Crohn's disease or ulcerative colitis who were also taking azathioprine or 6-mercaptopurine.
Patient Information Guide for Infliximab Injection
What It’s Used For
Infliximab is a TNF blocker used for several inflammatory conditions.
- Crohn's disease in adults, including fistulizing disease
- Crohn's disease in children 6 and older
- Ulcerative colitis in adults
- Ulcerative colitis in children 6 and older
- Rheumatoid arthritis, in combination with methotrexate
- Ankylosing spondylitis
- Psoriatic arthritis
- Chronic severe plaque psoriasis in adults who need systemic therapy
These uses are described in the Renflexis label evidence.
How It Works
Infliximab binds to TNF-alpha, an inflammation signal that is high in these diseases. By blocking it from reaching its receptors, it helps reduce inflammation. The label says the exact link between this action and clinical benefit is unknown.
Drug Class
Drug Class
- Tumor Necrosis Factor Blocker
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Tumor Necrosis Factor Blocker
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Tumor Necrosis Factor Receptor Blocking Activity
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Infliximab Injection in the FDA’s index.
From our Patient Information GuideInfliximab binds to TNF-alpha, an inflammation signal that is high in these diseases. By blocking it from reaching its receptors, it helps reduce inflammation. Read How Infliximab Injection Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Infliximab Injection in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Tumor necrosis factor alpha (TNF-alpha) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Remicade and Its Biosimilars
The FDA has approved 4 biosimilars to Remicade, the original infliximab, made by Janssen Biotech. It rates none of them interchangeable.
The original
Remicade
infliximab
Made by Janssen Biotech · FDA‑approved 1998
Its 4 biosimilars
- Inflectra infliximab-dyyb Made by Celltrion · FDA‑approved April 2016 Biosimilar, not rated interchangeable
- Renflexis infliximab-abda Made by Samsung Bioepis · FDA‑approved April 2017 Biosimilar, not rated interchangeable
- Ixifi infliximab-qbtx Made by Pfizer Ireland Pharmaceuticals · FDA‑approved December 2017 Biosimilar, not rated interchangeable The FDA lists it as discontinued
- Avsola infliximab-axxq Made by Amgen · FDA‑approved December 2019 Biosimilar, not rated interchangeable
Also infliximab, and not biosimilars: Zymfentra (Celltrion, 2023). The FDA lists it as an original product of its own.
What Is a Biosimilar?
- A biologic is made in living cells, not mixed from chemicals, so no copy of one is exactly identical. That is why a copy is called a biosimilar, not a generic.
- The FDA approves a biosimilar only when it is highly similar to the original and has no clinically meaningful differences in safety or in how well it works.
- It may be approved for fewer uses than the original, and may not come in every strength or device. Its own label lists what it is approved for.
What Does Interchangeable Mean?
- An interchangeable biosimilar can be given in place of the original at the pharmacy without your prescriber writing a new prescription, where state law allows, the way a generic can.
- A biosimilar without that rating works the same way, but needs a prescription written for it.
Why Four Letters After the Name?
- The FDA gives each biologic it licenses now four letters of its own, such as the letters dyyb in infliximab-dyyb. They mean nothing on their own.
- They tell one company’s product from another’s in your records and in safety reports.
Which one will I get? That depends on your prescription, your insurance plan and your pharmacy. Your pharmacist can tell you which one you have and whether a switch is possible.
From the FDA’s Purple Book, its list of licensed biologics, checked November 2026. The definitions follow the FDA’s biosimilar pages.
Dosage
Infliximab is given as an IV infusion by a healthcare professional. Renflexis is infused over at least 2 hours.
- Treatment usually begins with doses at 0, 2 and 6 weeks.
- After that, doses are given every 6 to 8 weeks depending on the condition.
- Your prescriber sets your dose and schedule. If you miss an infusion, contact your care team.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Crohn's disease
Adults · Weeks 0, 2 and 6 Starting dose 5 mg/kg at 0, 2 and 6 weeks
- 5 mg/kg intravenous infusion at 0, 2 and 6 weeks
Adults · Every 8 weeks after induction Usual dose 5 mg/kg every 8 weeks
- 5 mg/kg every 8 weeks thereafter
- For patients who respond and then lose response, consideration may be given to 10 mg/kg every 8 weeks
Good to know
Patients who do not respond by Week 14 are unlikely to respond with continued dosing
Children 6 years old and older · Weeks 0, 2 and 6 Starting dose 5 mg/kg at 0, 2 and 6 weeks
- 5 mg/kg intravenous infusion at 0, 2 and 6 weeks
Ulcerative colitis
Adults · Weeks 0, 2 and 6 Starting dose 5 mg/kg at 0, 2 and 6 weeks
- 5 mg/kg intravenous infusion at 0, 2 and 6 weeks
What ulcerative colitis is: Long-term inflammation and ulcers in the lining of the large bowel, causing diarrhea with blood and belly pain.
Adults · Every 8 weeks after induction Usual dose 5 mg/kg every 8 weeks
- 5 mg/kg every 8 weeks thereafter
Children 6 years old and older · Weeks 0, 2 and 6 Starting dose 5 mg/kg at 0, 2 and 6 weeks
- 5 mg/kg intravenous infusion at 0, 2 and 6 weeks
Rheumatoid arthritis
Adults · Weeks 0, 2 and 6 Starting dose 3 mg/kg at 0, 2 and 6 weeks
- 3 mg/kg intravenous infusion at 0, 2 and 6 weeks
Adults · Every 8 weeks after induction Usual dose 3 mg/kg every 8 weeks Highest dose 10 mg/kg every 8 weeks
- 3 mg/kg every 8 weeks thereafter
- For incomplete response, consideration may be given to adjusting up to 10 mg/kg every 8 weeks or treating as often as every 4 weeks
Good to know
Risk of serious infections is increased at higher doses per infusion or more frequent dosing
Ankylosing spondylitis
Adults · Weeks 0, 2 and 6 Starting dose 5 mg/kg at 0, 2 and 6 weeks
- 5 mg/kg intravenous infusion at 0, 2 and 6 weeks
Adults · Every 6 weeks after induction Usual dose 5 mg/kg every 6 weeks
- 5 mg/kg every 6 weeks thereafter
Psoriatic arthritis
Adults · Weeks 0, 2 and 6 Starting dose 5 mg/kg at 0, 2 and 6 weeks
- 5 mg/kg intravenous infusion at 0, 2 and 6 weeks
Good to know
Can be used with or without methotrexate
Adults · Every 8 weeks after induction Usual dose 5 mg/kg every 8 weeks
- 5 mg/kg every 8 weeks thereafter
Good to know
Can be used with or without methotrexate
Side Effects
The most common side effects are:
Common side effects
- Infections such as colds, sinus infections and sore throat
- Infusion-related reactions (shortness of breath, flushing, rash)
- Headache
- Abdominal pain
- Fever or chills during an infusion
- Urinary tract infections
When to get medical help
- Fever, chills, cough, weight loss or fatigue that could signal a serious infection, including tuberculosis
- Trouble breathing, chest pain, swelling of the face, hives or low blood pressure during or soon after an infusion
- Yellowing of the skin or eyes (jaundice) or other signs of liver problems
- New or worsening heart failure symptoms, such as shortness of breath or swelling
- Unusual bruising, bleeding or paleness, which can signal low blood counts
- Lupus-like symptoms after starting treatment
- New numbness, tingling or vision or nerve problems, which can signal demyelinating disease
- Any new lump, skin change or other sign of cancer
Serious reactions include severe infections, serious allergic reactions during infusion, liver problems and heart problems. Seek medical help right away for these.
Warnings and Precautions
The biggest risk is serious infection, including tuberculosis and fungal infections. You should be tested for TB and hepatitis B before starting.
- Lymphoma and other cancers have been reported.
- Liver injury, heart failure and low blood counts can occur.
- Serious infusion reactions, including anaphylaxis, are possible.
- Nerve problems and lupus-like illness can occur.
Interactions
Some medicines should not be combined with infliximab.
- Anakinra, abatacept or tocilizumab: higher infection risk
- Other biologics for the same conditions: not recommended
- Live vaccines: should not be given at the same time
- Warfarin, cyclosporine, theophylline: may need monitoring
- Azathioprine or 6-mercaptopurine: may raise lymphoma risk
Interactions Listed in the FDA-Approved Label
From the Infliximab Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Anakinra or abataceptWhat happensIncreased risk of serious infections with no added clinical benefit was seen with other TNF-blocking agents.What to doThe combination is not recommended.
-
TocilizumabWhat happensPossibility of increased immunosuppression and increased risk of infection with biological DMARDs such as TNF antagonists.What to doUse in combination should be avoided.
-
Other biological therapeutics used to treat the same conditionsWhat happensCombination with other biologics for the same conditions.What to doThe combination is not recommended.
-
What happensSpecific interaction studies have not been conducted; concomitant MTX may decrease anti-drug antibody production and increase infliximab concentrations.
-
ImmunosuppressantsWhat happensPatients with Crohn's disease who received immunosuppressants tended to have fewer infusion reactions.
-
Corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylatesWhat happensSerum infliximab concentrations appeared unaffected by baseline use of these Crohn's disease medications.
-
CYP450 substrates with a narrow therapeutic index For example: warfarin, cyclosporine, theophyllineWhat happensFormation of CYP450 enzymes could be normalized when infliximab products antagonize cytokine activity.What to doMonitor effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) on starting or stopping; the dose may be adjusted as needed.
-
Live vaccinesWhat happensLive vaccines not recommended concurrently, nor to infants after in utero exposure for at least 6 months following birth.What to doDo not give live vaccines concurrently.
-
Therapeutic infectious agentsWhat happensNot recommended concurrently with RENFLEXIS.What to doDo not give concurrently.
Read the label’s full interactions text
7 DRUG INTERACTIONS Use with anakinra or abatacept– increased risk of serious infections 7.1 Use with Anakinra or Abatacept An increased risk of serious infections was seen in clinical studies of other TNFα-blocking agents used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF-blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNFα-blocking agents. Therefore, the combination of RENFLEXIS and anakinra or abatacept is not recommended. 7.2 Use with Tocilizumab The use of tocilizumab in combination with biological DMARDs such as TNF antagonists, including RENFLEXIS, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. 7.3 Use with Other Biological Therapeutics The combination of RENFLEXIS with other biological therapeutics used to treat the same conditions as RENFLEXIS is not recommended. 7.4 Methotrexate (MTX) and Other Concomitant Medications Specific drug interaction studies, including interactions with MTX, have not been conducted. The majority of patients in rheumatoid arthritis or Crohn's disease clinical studies received one or more concomitant medications. In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. Concomitant Crohn's disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates. In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as NSAIDs, folic acid and corticosteroids. Concomitant MTX use may decrease the incidence of anti-drug antibody production and increase infliximab product concentrations.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Tell your doctor about any infection, TB exposure or travel to areas with fungal infections.
- Renflexis above 5 mg/kg should not be used in moderate to severe heart failure.
- Do not use after a severe allergic reaction to infliximab or if allergic to murine proteins.
- Pregnancy: infliximab crosses the placenta, so delay live vaccines for infants for at least 6 months.
- Breastfeeding: low levels appear in milk.
- Children under 6 have not been studied for Crohn's disease or ulcerative colitis.
Overdose
Single doses up to 20 mg/kg have been given without direct toxic effects. If too much is given, you should be monitored for side effects and treated for symptoms right away.
Half-Life and How Your Body Processes It
Infliximab stays mainly in the bloodstream. Its half-life is about 7.7 to 9.5 days. It does not build up with repeated dosing at 4 or 8 week intervals. If your body makes antibodies to infliximab, it clears the drug faster.
Storage
Store unopened Infliximab vials in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Stored at room temperatures up to a maximum of 30 °C (86 °F) for a single period of up to 6 months but not exceeding the original expiration date.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Infliximab Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Infliximab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is infliximab used for?
How is infliximab given?
What side effects should I expect?
When should I call my doctor?
Do I need tests before starting infliximab?
Is infliximab safe in pregnancy?
Is infliximab injection available over the counter?
When was infliximab injection first available?
Who makes infliximab injection?
What is the brand name of infliximab injection?
What is the generic name of Inflectra?
What drug class is infliximab injection?
What strengths does infliximab injection come in?
How much does infliximab injection cost?
Where can I read the infliximab injection prescribing information (package insert)?
Is there a biosimilar for Remicade?
Is infliximab injection gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Infliximab Injection
Skip the scrolling. Ask in your own words and get an answer from Infliximab Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Infliximab Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Infliximab Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Infliximab Injection Forms and Strengths (How It Comes)
Infliximab Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Infliximab Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Renflexis is used for Crohn's disease, ulcerative colitis, rheumatoid arthritis (with methotrexate), ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
- Renflexis is given by IV infusion over at least 2 hours with an in-line filter.
- Renflexis powder is mixed and diluted by a trained medical professional before use.
- Renflexis should not be infused in the same IV line with other agents.
- Renflexis infusions are given where staff can treat infusion reactions if they occur.
Infliximab Injection on the U.S. Market: Products, Makers and Brands
How Infliximab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
2 companies list 3 Infliximab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1998. Brand names in the directory today include Renflexis and Remicade; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished injection, powder, lyophilized, for solution (3) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Infliximab Injection Is Used (Medicaid Data)
How many Infliximab Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Infliximab Injection prescribed? Of the 1,682 medications we measure, Infliximab Injection ranks #516 by Medicaid prescriptions — more than 69% of them.
Utilization by Infliximab Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
infliximab 100 MG Injection Most dispensed
2 of 4 listed NDCs had Medicaid claims. RxNorm 310994
infliximab-dyyb 100 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 1790541
infliximab-abda 100 MG Injection
1 of 4 listed NDCs had Medicaid claims. RxNorm 1927285
infliximab-axxq 100 MG Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 2266525
1 ML infliximab-dyyb 120 MG/ML Pen Injector
2 of 4 listed NDCs had Medicaid claims. RxNorm 2675742
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 7 of the 15 listed Infliximab Injection NDCs had Medicaid claims.
Compare Infliximab Injection Products
A representative set of FDA-listed product records for Infliximab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 mg/10 mL | Intravenous | Janssen Biotech, Inc. × 2 listings | BLA | View NDC → |
| 100 mg | Intravenous | Organon LLC | BLA | View NDC → |
Showing 3 of 3 products — FDA National Drug Code Directory. See every product, package size and price: browse all 3 Infliximab Injection NDCs →
Infliximab Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Infliximab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Infliximab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Infliximab Injection FDA Approval History
How Infliximab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Infliximab Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Infliximab recalls since July 2021.
✅No Infliximab recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Infliximab Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 3
- Strengths
- 6
- Forms in current FDA listings
- 3 of 3
RxCUI 191831 -
Dose form (SCDF) Pen InjectorIn current FDA listings
RxCUI 2675740Its strength (SCD)-
1 mL infliximab-dyyb 120 mg/mL
RxCUI 2675742
-
1 mL infliximab-dyyb 120 mg/mL
-
Dose form (SCDF) Prefilled SyringeIn current FDA listings
RxCUI 2675751Its strength (SCD)-
1 mL infliximab-dyyb 120 mg/mL
RxCUI 2675753
-
1 mL infliximab-dyyb 120 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Infliximab Injection Supply and Shortage Status
Whether Infliximab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Infliximab Injection Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Infliximab Injection: the national average from CMS’s weekly NADAC survey, as of Mar 11, 2026. It is the pharmacy’s cost, not your price at the counter.
How the Pharmacy Price Has Changed
Pick a strength to see how its price has changed since Apr 2024.
For brand-name Remicade, the 100 mg/10 mL injection, pharmacies paid an average of $1,135.97 each as of Mar 11, 2026, the same as a year earlier.
- What pharmacies pay now
- $1,135.97
- each, as of Mar 11, 2026
- Last 4 weeks
- No change
- from $1,135.97 on Feb 11, 2026
- Last 12 months
- No change
- from $1,135.97 on Mar 12, 2025
- Lowest and highest since Apr 2024
- $1,135.97 to $1,135.99
- each
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Mar 2026 | $1,135.97 |
| Feb 2026 | $1,135.97 |
| Jan 2026 | $1,135.97 |
| Dec 2025 | $1,135.97 |
| Nov 2025 | $1,135.97 |
| Oct 2025 | $1,135.97 |
| Sep 2025 | $1,135.97 |
| Aug 2025 | $1,135.97 |
| Jul 2025 | $1,135.97 |
| Jun 2025 | $1,135.97 |
| May 2025 | $1,135.97 |
| Apr 2025 | $1,135.97 |
| Mar 2025 | $1,135.97 |
| Feb 2025 | $1,135.97 |
| Jan 2025 | $1,135.97 |
| Dec 2024 | $1,135.97 |
| Nov 2024 | $1,135.99 |
| Oct 2024 | $1,135.99 |
| Sep 2024 | $1,135.99 |
| Aug 2024 | $1,135.99 |
| Jul 2024 | $1,135.99 |
| Jun 2024 | $1,135.99 |
| May 2024 | $1,135.99 |
| Apr 2024 | $1,135.99 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Injection · Intravenous | 100 mg/10 mL | Remicade (brand) | $1,135.97 each | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Infliximab Injection Brand Names
Infliximab Injection has 5 brand names on record: Inflectra, Renflexis, Remicade, Avsola and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Infliximab Injection: Manufacturers and Labelers
2 companies list Infliximab Injection products with the FDA. By number of product records, the largest are Janssen Biotech, Inc., Organon LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Infliximab Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Organon LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →